在试验中既往报道有关的伊洛前列素并无意外不良反应出现。
Otherwise no unexpected adverse effects were seen in the trial beyond those reported previously for iloprost.
前言：目的：介绍治疗原发性肺动脉高压的吸入性伊洛前列素。
Objective: To introduce inhaled iloprost for the treatment of primary pulmonary hypertension.
在治疗初始和终末呼吸困难评估在安慰剂组和伊洛前列素组之间类似。
Dyspnoea measures were similar between placebo and iloprost at baseline and at the end of therapy.
应用推荐